Alnylam Pharmaceuticals Inc (ALNY)vsVerizon Communications Inc (VZ)
ALNY
Alnylam Pharmaceuticals Inc
$297.45
-1.02%
HEALTHCARE · Cap: $39.39B
VZ
Verizon Communications Inc
$48.35
-0.42%
COMMUNICATION SERVICES · Cap: $197.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Verizon Communications Inc generates 3146% more annual revenue ($139.15B vs $4.29B). ALNY leads profitability with a 12.6% profit margin vs 12.5%. ALNY appears more attractively valued with a PEG of 0.50. VZ earns a higher WallStSmart Score of 68/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
VZ
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.6%
Fair Value
$2401.68
Current Price
$297.45
$2104.23 discount
Margin of Safety
-31.3%
Fair Value
$36.74
Current Price
$48.35
$11.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Attractively priced relative to earnings
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 25.2%
Generating 3.8B in free cash flow
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 36.9x book value
2.9% revenue growth
4.3% earnings growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : VZ
The strongest argument for VZ centers on P/E Ratio, Market Cap, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.1x leaves little room for execution misses.
Bear Case : VZ
The primary concerns for VZ are Revenue Growth, EPS Growth, Debt/Equity. Debt-to-equity of 1.90 is elevated, increasing financial risk.
Key Dynamics to Monitor
ALNY profiles as a growth stock while VZ is a value play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.30 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
VZ generates stronger free cash flow (3.8B), providing more financial flexibility.
Bottom Line
VZ scores higher overall (68/100 vs 65/100). ALNY offers better value entry with a 86.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Verizon Communications Inc
COMMUNICATION SERVICES · TELECOM SERVICES · USA
Verizon Communications Inc. is an American multinational telecommunications conglomerate and a corporate component of the Dow Jones Industrial Average. The company is headquartered at 1095 Avenue of the Americas in Midtown Manhattan, New York City, but is incorporated in Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?